<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04131595</url>
  </required_header>
  <id_info>
    <org_study_id>WEV-MVA-001</org_study_id>
    <nct_id>NCT04131595</nct_id>
  </id_info>
  <brief_title>Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects</brief_title>
  <official_title>Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bavarian Nordic</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>JPM CBRN Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bavarian Nordic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess safety and tolerability as well as immune responses to the MVA-BN-WEV vaccine in
      the 3 treatment groups receiving different doses.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 7, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability: Number of subjects reporting any serious adverse events (SAE)</measure>
    <time_frame>within 7 months after vaccinations of subjects</time_frame>
    <description>Number of subjects reporting any serious adverse events (SAE)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Equine Encephalitis</condition>
  <arm_group>
    <arm_group_label>MVA-BN-WEV Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment Group 1 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 107 Inf.U in 0.5 mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVA-BN-WEV Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment Group 2 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 1 x 108 Inf.U in 0.5 mL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MVA-BN-WEV Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in treatment Group 3 will receive 2 administrations 4 weeks apart with MVA-BN-WEV vaccine of 2 x 108 Inf.U in 2 x 0.5 mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-WEV Dose 1</intervention_name>
    <description>1 x 10^7 Inf.U MVA-BN-WEV vaccine</description>
    <arm_group_label>MVA-BN-WEV Dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-WEV Dose 2</intervention_name>
    <description>1 x 10^8 Inf.U MVA-BN-WEV vaccine</description>
    <arm_group_label>MVA-BN-WEV Dose 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-BN-WEV Dose 3</intervention_name>
    <description>2 x 10^8 Inf.U MVA-BN-WEV vaccine.</description>
    <arm_group_label>MVA-BN-WEV Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male and female subjects ≥18 and ≤50 years of age at screening (SCR).

          -  2. General good health, without clinically relevant medical illness, physical exam
             findings, or laboratory abnormalities, as determined by the investigator.

          -  3. Prior to performance of any trial specific procedures, the subject has read, signed
             and dated an informed consent form (ICF), having been advised of the risks and
             benefits of the trial in a language understood by the subject, and has signed the
             Health Insurance Portability and Accountability Act authorization form (HIPAA).

          -  4. Body mass index (BMI) ≥18.5 and ≤35.

          -  5. Female subjects of childbearing potential and male subjects who are sexually active
             with a female partner of childbearing potential must agree to the use of an effective
             method of birth control from at least 30 days prior to administration of the vaccine
             to until 30 days after the last vaccination. A woman is considered of childbearing
             potential unless post-menopausal (defined as ≥12 months without a menstrual period at
             SCR) or surgically sterilize (bilateral oophorectomy, bilateral tubal ligation,
             hysterectomy). Acceptable contraception methods are restricted to abstinence
             (abstinence only acceptable if refraining from heterosexual intercourse during the
             entire period of 30 days prior to administration of the vaccine until 30 days after
             the last vaccination), double barrier contraceptives, vasectomy, intrauterine
             contraceptive devices or licensed hormonal products.

          -  6. Women of Childbearing Potential (WOCBP) must have a negative serum pregnancy test
             at SCR.

          -  7. Negative human immunodeficiency virus antibody test (anti-HIV), negative hepatitis
             B surface antigen (HBsAG) and negative antibody to hepatitis C virus.

          -  8. Troponin I within normal limits at SCR.

        Exclusion Criteria:

          -  1. Pregnant or breast-feeding women.

          -  2. Subject has an acute or chronic medical condition that, in the opinion of the
             investigator, would render the trial procedures unsafe or would interfere with the
             evaluation of the responses, including but not limited to, neurologic, cardiovascular,
             respiratory, hepatic, hematologic, rheumatologic, endocrine, gastrointestinal, renal,
             autoimmune, or immunosuppressive conditions.

          -  3. Laboratory parameters (such as complete blood count, serum biochemistry including
             aspartate aminotransferase (AST), alanine amino transferase (ALT), alkaline
             phosphokinase (AP), bilirubin, or creatinine values), pulse rate and/or blood
             pressure, or electrocardiogram (ECG) outside normal range at SCR and deemed clinically
             relevant by the investigator.

          -  4. History of or active autoimmune disease; persons with vitiligo or thyroid disease
             taking thyroid replacement are not excluded. History of Guillain-Barré syndrome or
             Reye's syndrome.

          -  5. Known or suspected impairment of immunologic functions including, but not limited
             to, clinically significant liver disease, diabetes mellitus type I, moderate to severe
             kidney impairment. A known immunodeficiency syndrome.

          -  6. Known or suspected previous smallpox vaccination or vaccination with a
             poxvirus-based vaccine.

          -  7. Known or suspected previous alphavirus infections (Eastern Equine Encephalitis
             Virus (EEEV), Venezuelan Equine Encephalitis Virus (VEEV), Western Equine Encephalitis
             Virus (WEEV), Chikungunya).

          -  8. History of malignancy other than squamous cell or basal cell skin cancer, unless
             there has been surgical excision at least 6 months prior to SCR that is considered to
             have achieved cure. Subjects with history of skin cancer must not be vaccinated at the
             previous tumor site.

          -  9. Clinically significant mental disorder not adequately controlled by medical
             treatment.

          -  10. Active or recent history of chronic alcohol abuse and/or intravenous and/or nasal
             drug abuse (within the time period of 6 months before SCR).

          -  11. History of allergic disease or reactions likely to be exacerbated by any component
             of the vaccine, e.g. tris(hydroxymethyl)-amino methane, chicken embryo fibroblast
             proteins, gentamicin, ciprofloxacin.

          -  12. Known allergy to eggs.

          -  13. History of anaphylaxis or severe allergic reaction to any vaccine.

          -  14. Having received any vaccinations or planned vaccinations with a live vaccine
             within 30 days prior to first or after last trial vaccination.

          -  15. Having received any vaccinations or planned vaccinations with an inactivated
             vaccine within 14 days prior to first or after last trial vaccination.

          -  16. Recent blood donation (including platelets, plasma and red blood cells) within 4
             weeks prior screening, or planned blood donations during active trial phase (until EAP
             Visit).

          -  17. Chronic systemic administration (defined as more than 14 days) of &gt;5 mg prednisone
             (or equivalent)/day or any other immunemodifying drugs during a period starting 3
             months prior to administration of the vaccine and ending at the last visit of the
             active treatment phase. The use of topical, inhaled, ophthalmic and nasal
             glucocorticoids is allowed.

          -  18. Post organ transplant subjects whether or not receiving chronic immunosuppressive
             therapy.

          -  19. Administration or planned administration of immunoglobulins and/or any blood
             products during a period starting 3 months prior to administration of the vaccine and
             ending at the last visit of the active treatment phase. Receipt of packed red blood
             cells given for an emergent indication in an otherwise healthy person, and not
             required as ongoing treatment is not exclusionary (for example packed red blood cells
             emergently given during an elective surgery).

          -  20. History of coronary heart disease, myocardial infarction, angina, congestive heart
             failure, cardiomyopathy, stroke or transient ischemic attack, uncontrolled high blood
             pressure, significant arrhythmia with or without corrective/ablative surgery, or any
             other heart condition under the care of a doctor.

          -  21. Use of any investigational or non-registered drug or vaccine other than the trial
             vaccine within 30 days preceding the first dose of the trial vaccine, or planned
             administration of such a drug during the trial period until the Follow-Up (FU) Visit 6
             months after the last vaccination visit.

          -  22. Clinical trial site personnel involved in this trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Fierro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>JCCT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 16, 2019</study_first_submitted>
  <study_first_submitted_qc>October 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>November 26, 2019</last_update_submitted>
  <last_update_submitted_qc>November 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalomyelitis, Equine</mesh_term>
    <mesh_term>Encephalitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

